Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for Dianthus Therapeutics (DNTH) over the last 7 years, with Dec 2024 value amounting to $22.8 million.

  • Dianthus Therapeutics' Cash & Equivalents rose 66.27% to $56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 66.27%. This contributed to the annual value of $22.8 million for FY2024, which is 82.78% down from last year.
  • As of FY2024, Dianthus Therapeutics' Cash & Equivalents stood at $22.8 million, which was down 82.78% from $132.3 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Cash & Equivalents registered a high of $132.3 million during FY2023, and its lowest value of $15.4 million during FY2022.
  • In the last 3 years, Dianthus Therapeutics' Cash & Equivalents had a median value of $22.8 million in 2024 and averaged $56.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 761.21% in 2023, then plummeted by 82.78% in 2024.
  • Dianthus Therapeutics' Cash & Equivalents (Yearly) stood at $15.4 million in 2022, then surged by 761.21% to $132.3 million in 2023, then crashed by 82.78% to $22.8 million in 2024.